ZA971717B - Method of reducing tissue damage associated with non-cardiac ischemia - Google Patents

Method of reducing tissue damage associated with non-cardiac ischemia

Info

Publication number
ZA971717B
ZA971717B ZA971717A ZA971717A ZA971717B ZA 971717 B ZA971717 B ZA 971717B ZA 971717 A ZA971717 A ZA 971717A ZA 971717 A ZA971717 A ZA 971717A ZA 971717 B ZA971717 B ZA 971717B
Authority
ZA
South Africa
Prior art keywords
tissue damage
cardiac ischemia
damage associated
reducing tissue
ischemia
Prior art date
Application number
ZA971717A
Other languages
English (en)
Inventor
Thomas A Beyer
Delvin R Knight Jr
Banavara L Mylari
Peter J Oates
Eric R Pettipher
Wayne R Tracey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA971717B publication Critical patent/ZA971717B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA971717A 1996-02-29 1997-02-27 Method of reducing tissue damage associated with non-cardiac ischemia ZA971717B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1270796P 1996-02-29 1996-02-29

Publications (1)

Publication Number Publication Date
ZA971717B true ZA971717B (en) 1998-08-27

Family

ID=21756300

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA971717A ZA971717B (en) 1996-02-29 1997-02-27 Method of reducing tissue damage associated with non-cardiac ischemia

Country Status (14)

Country Link
US (1) US6127367A (de)
EP (1) EP0792643B1 (de)
JP (1) JPH09316003A (de)
KR (1) KR970061252A (de)
CN (1) CN1081460C (de)
AT (1) ATE216239T1 (de)
AU (1) AU724327B2 (de)
CA (1) CA2198564C (de)
DE (1) DE69711972T2 (de)
DK (1) DK0792643T3 (de)
ES (1) ES2172748T3 (de)
IL (1) IL120264A0 (de)
PT (1) PT792643E (de)
ZA (1) ZA971717B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982306A3 (de) * 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph von Zopolrestat Monohydrat
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2002098421A1 (en) * 2001-06-05 2002-12-12 University Of Maryland, Baltimore Novel treatment for neurological and psychiatric disorders
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
ES2393271T3 (es) * 2005-12-16 2012-12-19 Sanwa Kagaku Kenkyusho Co., Ltd Agente para la prevención y tratamiento de la insuficiencia renal aguda
WO2007097301A1 (ja) * 2006-02-20 2007-08-30 Sanwa Kagaku Kenkyusho Co., Ltd. 脳卒中における脳虚血又は脳虚血再灌流障害の予防又は治療剤
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
ES2409930T3 (es) * 2007-01-31 2013-06-28 Sanwa Kagaku Kenkyusho Co., Ltd Agente protector del nervio de la retina o del nervio óptico
US8273746B2 (en) * 2007-03-23 2012-09-25 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
CN101809017A (zh) 2007-09-14 2010-08-18 阿斯利康(瑞典)有限公司 酞嗪酮衍生物
KR101598231B1 (ko) 2007-10-17 2016-02-26 쿠도스 파마슈티칼스 리미티드 4-[3-(4-시클로프로판카르보닐-피페라진-1-카르보닐)-4-플루오로-벤질]-2ｈ-프탈라진-1-온
EP2220216A4 (de) * 2007-11-15 2013-03-20 Univ Laval Verfahren zur regulation der prostaglandin f-synthase- (pgfs-)aktivität von akr1b1 und verwendungen davon
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
EP2346495B2 (de) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmazeutische formulierung 514
WO2012088525A2 (en) 2010-12-23 2012-06-28 The Board Of Regents Of The University Of Texas System Methods for treating copd
US10443185B2 (en) 2016-10-19 2019-10-15 Spectrum Brands, Inc. Portable steam generator base for iron
US20240033263A1 (en) 2021-03-18 2024-02-01 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2024053761A1 (ko) * 2022-09-07 2024-03-14 애니머스큐어 주식회사 알도오즈 환원효소 억제제를 포함하는 근원 세포 증식 및 분화 촉진용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4492706A (en) * 1983-08-01 1985-01-08 American Home Products Corporation Method of lowering lipid levels
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
EP0310931A3 (de) * 1987-10-08 1990-10-03 Ethyl Corporation Hühnerfutter
FR2665440B1 (fr) * 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
JP3049284B2 (ja) * 1990-11-07 2000-06-05 株式会社三和化学研究所 ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
AU711080B2 (en) * 1994-12-22 1999-10-07 Regents Of The University Of California, The Method for protecting the heart from ischemia
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
IL120264A0 (en) 1997-06-10
EP0792643A1 (de) 1997-09-03
DK0792643T3 (da) 2002-07-22
PT792643E (pt) 2002-08-30
DE69711972D1 (de) 2002-05-23
MX9701533A (es) 1998-06-30
US6127367A (en) 2000-10-03
JPH09316003A (ja) 1997-12-09
AU1501097A (en) 1997-09-04
CA2198564A1 (en) 1997-08-29
AU724327B2 (en) 2000-09-14
DE69711972T2 (de) 2002-08-29
KR970061252A (ko) 1997-09-12
EP0792643B1 (de) 2002-04-17
CN1081460C (zh) 2002-03-27
CA2198564C (en) 2000-06-27
ATE216239T1 (de) 2002-05-15
ES2172748T3 (es) 2002-10-01
CN1168794A (zh) 1997-12-31

Similar Documents

Publication Publication Date Title
ZA971717B (en) Method of reducing tissue damage associated with non-cardiac ischemia
AU3007897A (en) High fluence diode laser device and method for the fabrication and use thereof
AU6452498A (en) Retraction reel for keys and the like
AU2467297A (en) New benzimidazole derivatives with antihistaminic activity
AU3272995A (en) Protective prostaglandins for use in conjunction with chemotherapeutic agents
AU2719595A (en) 2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)methoxy-1,3- propanediol derivative
AU7553598A (en) Ellipsometer with two lasers
PH27278A (en) Spiro-isoquinoline-pyrrolidine tetrones useful as aldose reductase inhibitors
AU5315498A (en) Head for the linear dimension checking of mechanical pieces
AU2675299A (en) Monitor support with self-positioning guide track
DE69020394T2 (de) Aldose-Reductase-Inhibitor.
AU2654492A (en) Method for checking the working condition of an optically operated proximity switch
AU1500997A (en) Method of reducing tissue damage associated with ischemia
GB2277633B (en) High power laser amplifier
AU6058694A (en) Endoscope with retractable tool
GB2280538B (en) Method for the prevention of eye damage when using high-power lasers
AU1436000A (en) Auxiliary device for performing work above the head
AU2165897A (en) Non-genetically modified mammal as a model for multiple sclerosis
AUPQ050599A0 (en) Power actuated tool and shroud for use with the tool
GB2266406B (en) High-power laser source
SE9302552D0 (sv) Vaeltningshindrande skenstyrning foer smaelgaangstruckar
TJ99000570A (en) A method of plasty of the osteosoft-woven defects by the complex-compound scrap
ITMI930136V0 (it) Struttura di corpo illuminante con fascio luminoso rotante, particolarmente per veicoli e simili
AUPO301496A0 (en) Combination jack & turntable
GB9308567D0 (en) The battery inhibitor